Phase 1 Motor Neurone Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are willing to take part and sign a consent form before any study procedures begin.
• You are 18 years of age or older at the time you sign the consent form.
• You have been diagnosed with ALS (also known as Lou Gehrig's disease) according to recognised international diagnostic guidelines.
• You have a confirmed genetic change (mutation) in the SOD1 gene.
• Your lung breathing capacity is at least 50% of what would normally be expected for someone of your sex, age, and height, measured while sitting.
• If you are already taking riluzole or edaravone (common ALS medications), you have been on a steady, unchanged dose for at least 30 days before the study starts and plan to stay on that dose throughout the study.

Who may not be able to join:

• You have a specific type of SOD1 gene mutation known as p.F21C (confirm with trial site).
• You have received another experimental drug, biological treatment, or medical device within the past month or within a certain timeframe based on how long that treatment stays in the body — whichever is longer.
• You have previously received treatments such as small interfering RNA therapy, stem cell therapy, or gene therapy.
• You are currently taking part in another clinical trial that involves a treatment or intervention.
• You have a history of, or have tested positive for, HIV, hepatitis C, or hepatitis B.
• You are currently pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.